IGF-1 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-19. Numbers and descriptions here follow the published literature rather than marketing material.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
=== 24 February === The SAF claimed to have taken the eastern part of the Soba Bridge. The SAF said that it had partially broken the siege of Dalang and captured the Al-Karkal, Koli, and Kiqa regions north of Kadugli and Hajar Al-Jawad and Karkariya to the south. The RSF claimed to have shot down an Ilyushin fighter jet over Nyala, killing its crew. The pilot was later identified as Major General Abulgasem Ali. The National Umma Party removed Fadlallah Burma Nasir as its acting leader following his cosigning of the Government of Peace and Unity agreement with the RSF. In response, Nasir ordered the dissolution of the party's Presidential Institution.
It is unknown whether intensive or conventional blood glucose control is better for diabetic foot ulcer healing. A 2020 Cochrane systematic review evaluated the effects of nutritional supplements or special diets on healing foot ulcers in people with diabetes. The review authors concluded that it's uncertain whether nutritional interventions have an effect on foot ulcer healing and that more research is needed to answer this question. Skin grafting and tissue replacements can help improve the healing of diabetic foot ulcers. A 2021 systematic review concluded that there was no strong evidence about the effects of psychological therapies on diabetic foot ulcer healing and recurrence.
Alongside continued research defensive countermeasures there has been a proliferation of nuclear weapons around the world. Many nations have acquired technology required to produce nuclear weapons since the end of the Cold War. India tested its first nuclear weapon with Operation Smiling Buddha in 1974. It was followed by Pakistan's nuclear program acquiring centrifuges capable of enriching uranium in the 80's and in 1998 was able to conduct several underground tests. Today the United States, Russia, the United Kingdom, France, and China all possess nuclear weapons and have signed the Nuclear Non-Proliferation Treaty in an attempt to curb the spread of nuclear weapons. India, Pakistan, Israel and North Korea are also in possession of nuclear technology but have not signed the Nuclear Non-Proliferation Treaty. The Cold War brought with it increased research into radio technology as well as nuclear weapons. The success of Sputnik 1 lead to an increase funding for radio telescopes such as Jodrell Bank Observatory for use in tracking Sputnik and possible nuclear launches by the Soviet Union. Jodrell Bank and other observatories like it have since been used to track space probes as well as investigate quasars, pulsars, and meteoroids. Satellites such as the Vela that were originally launched to detect nuclear detonation following the Partial Nuclear Test Ban Treaty have been used since then to discover and further investigate gamma-ray bursts. A new space race began in the 2020s, largely between the United States' Artemis Program and China's Lunar Exploration Program.
=== Other research === As of July 2013, afamelanotide was in phase II and III clinical trials for vitiligo and other skin diseases. A medication for rheumatoid arthritis, tofacitinib, has been tested for the treatment of vitiligo. According to a 2021 review, JAK inhibitors like ruxolitinib show promise in targeting the IFN-γ-chemokine signaling axis implicated in vitiligo pathogenesis and improving NSV. In mid-2026, pharmaceutical corporation Pfizer announced positive phase III trial results of ritlecitinib, a kinas-inhibiting drug, to treat NSV. Additionally, a 2026 study published in The Lancet showed positive results with the JAK inhibitor upadacitinib. As of 2024, mitochondrial antioxidants, NRF2 inhibitors, and TBK1 inhibitors were emerging as potential therapeutic options to block the effects of melanocytic mtDNA release associated with vitiligo. The head of a 2025 Osaka Metropolitan University research team suggested that its discoveries, which included the presence of dormant pigment cells in vitiligo patches, could lead to new treatment approaches.
A person with idiopathic carpal tunnel syndrome will not have any sensory loss over the thenar eminence (bulge of muscles in the palm of the hand and at the base of the thumb). This is because the palmar branch of the median nerve, which innervates that area of the palm, separates from the median nerve and passes over the carpal tunnel.
Sources: en.wikipedia.org
== History and synthesis == DMF was first obtained in 1893 by the French chemist Albert Verley (1867–1959), by distilling a mixture of dimethylamine hydrochloride and potassium formate. It is now industrially manufactured by combining methyl formate and dimethylamine or by reaction of dimethylamine with carbon monoxide. Although currently impractical, DMF can be prepared from supercritical carbon dioxide using ruthenium-based catalysts.
== Development == Zhonghua Fu runs a clinic in Nanjing, China, affiliated with Nanjing University of Chinese Medicine. At the FSN clinic for pain medicine, FSN is used as the sole means to treat musculoskeletal disorders and some chronic benign visceral disorders. Fu originally trained as a TCM doctor, completing his masters in acupuncture. While practicing and teaching traditional acupuncture in Guangzhou, he realized that several innovations were needed to improve and accelerate the acupuncture effect. Because some techniques for painful problems in the ancient Huangdi Neijing were punctured obliquely surrounding some painful spots, Fu thought inserting horizontally was a good choice, and then FSN came into being after a number of trials. After completing his Ph.D., Fu conducted research in his lab for two years on arthritic rats. During these trials, when the needle was inserted into the local point of sensitivity, there were no profound changes in VAS and range of motion. Notable changes in VAS and range of motion were observed however when the needle was inserted parallel to the skin surface.
The Healthcare Facilities Accreditation Program (HFAP) is a not-for-profit organization meant to help healthcare organizations maintain their standards in patient care and comply with regulations and the healthcare environment. Headquartered in Chicago, HFAP is an accreditation organization with authority from Centers for Medicare and Medicaid Services. HFAP provides accreditation programs for hospitals, clinical laboratories, ambulatory surgical centers, office based surgery, and critical access hospitals. HFAP also accredits mental health and physical rehabilitation facilities and provides certification for primary stroke centers. HFAP was founded in 1943 by the American Osteopathic Association, a medical organization representing osteopathic physicians.
On 14 December 1895, there was a large outbreak of botulism in the Belgian village of Ellezelles that occurred at a funeral where people ate pickled and smoked ham; three of them died. By examining the contaminated ham and performing autopsies on the people who died after eating it, van Ermengem isolated an anaerobic microorganism that he called Bacillus botulinus. He also performed experiments on animals with ham extracts, isolated bacterial cultures, and toxins extracts from the bacteria. From these he concluded that the bacteria themselves do not cause foodborne botulism, but rather produce a toxin that causes the disease when ingested. As a result of Kerner's and van Ermengem's research, it was thought that only contaminated meat or fish could cause botulism. This idea was refuted in 1904 when a botulism outbreak occurred in Darmstadt, Germany, because of canned white beans. In 1910, the German microbiologist J. Leuchs published a paper showing that different strains of Bacillus botulinus caused the outbreaks in Ellezelles and Darmstad and that the toxins were serologically distinct. In 1917, Bacillus botulinus was renamed Clostridium botulinum, as it was decided that the term Bacillus should refer to a group of aerobic microorganisms, while Clostridium would be used only to describe a group of anaerobic microorganisms. In 1919, Georgina Burke used toxin-antitoxin reactions to identify two strains of Clostridium botulinum, which she designated A and B.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.